Glyco-oxidation and cardiovascular complications in type 2 diabetes: A clinical update

Acta Diabetologica

Volumn 50, Issue 2, 2013, Pages 101-110

  Piarulli, Francesco ^a   Sartore, Giovanni ^a   Lapolla, Annunziata ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cardiovascular complications; Glyco oxidation; Receptor for advanced glycation end products; Type 2 diabetes

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CELL RECEPTOR; LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROSS LINKING; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM LESION; GLUCOSE OXIDATION; GLYCATION; HUMAN; ISCHEMIC HEART DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84878260579     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0412-3     Document Type: Review

References (73)

1. Diabetes Vital Statistics (1996) American Diabetes Association, Virginia
2. Jay RH, Betteridge DJ (1994) The heart and macrovascular disease in diabetes mellitus. In: Pickup JC, Williams G (eds) Chronic complications of diabetes. Blackwell Press, Melbourne, pp 195-212
3. Pyorala K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524
4. Yegin A, Ozben T, Yegin H (1995) Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 25:157-161
5. Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, Arakawa K, Nagai R, Horiuchi S, Itabe H, Takano T (2000) In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 150:343-355
6. Witztum JL (1994) The oxidation hypothesis of atherosclerosis. Lancet 344:793-795
7. Kuyvenhoven JP, Meinders AE (1999) Oxidative stress and diabetes mellitus: pathogenesis of long-term complications. Eur J Int Med 10:9-19
8. Lapolla A, Piarulli F, Sartore G, Rossetti C, Martano L, Carraro P, De Paoli M, Fedele D (2003) Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 89:91-96
9. Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87-101
10. Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003) Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169
11. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582-592
12. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 4:813-820
13. Giuliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267
14. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321
15. Thornalley PJ (1996) Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3:149-166
16. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9
17. Lapolla A, Fedele D, Traldi P (2001) Diabetes and mass spectrometry. Diabetes Metab Res Rev 17(2):99-112
18. Lapolla A, Gerhardinger G, Pelli B et al (1990) Absence of brown products FFI in non-diabetic and diabetic rat collagen. Diabetes 39:57-61
19. Lapolla A, Baldo L, Aronica R et al (1994) Matrix assisted laser desorption ionization mass spectrometric studies on protein glycation. The reaction of ribonuclease with hexoses. Biol Mass Spectrom 23:241-248
20. Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23:1-34
21. Lapolla A, Porcu S, Traldi P (2011) Some views on proteomics in diabetes. Clin Chem Lab Med 49(6):943-957
22. Ahmed N, Babei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ (2005) Degradation products of protein damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590-1603
23. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)-carboxymethyllysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 44:31740-31749
24. Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J Clin Invest 99:457-468
25. Yoshida N, Okumura K, Aso Y (2005) High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54:345-350
26. Sell D, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing insulin-dependent diabetes mellitus. Diabetes 41:1286-1292
27. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30:670-676
28. Sing R, Barden A, Mori T, Beilin L (2001) Advanced glycation end products: a review. Diabetologia 44:129-146
29. Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 94:110-117
30. Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC (1990) Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 39:807-814
31. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403
32. Sakata N, Uesugi N, Takebayashi S, Nagai R, Jono T, Horiuchi S, Takeya M, Itabe H, Takano T, Myint T, Tamgiuchi N (2001) Glycoxidation and lipid peroxidation of low density lipoprotein can synergistically enhance atherogenesis. Cardiovasc Res 49:466-475
33. Moro E, Alessandrini P, Zambon C (1999) Is glycation of LDL in patients with type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16(8):663-669
34. Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D (2005) Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 28:653-657
35. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622
36. Maxwell SR, Thomason H, Sandler D, Leguen C, Thorpe GH, Jones AF, Barnett AH (1997) Antioxidant status in patients with uncomplicated insulin-dependent and noninsulin-dependent diabetes mellitus. Eur J Clin Invest 271:484-490
37. Stehouwer CDA (1997) von Willebrand factor, dysfunction of the vascular endothelium, and the development of renal and vascular complications in diabetes. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus. Kluwer, Boston, pp 155-163
38. Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Nollino L, Cosma C, Fedele D, Lapolla A (2009) Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 52:1419-1425
39. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 114:597-605
40. Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM (2000) RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 26:485-493
41. Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196:9-21
42. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742-752
43. Kalea AZ, Schmidt AM, Hudson BI (2009) RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 116:621-637
44. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058-1070
45. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109
46. Vazzana N, Santilli F, Cuccurullo C, Davì G (2009) Soluble forms of RAGE in internal medicine. Int Emerg Med 4:389-401
47. Nawroth PP, Stern DM (2007) Soluble forms of RAGE: an index of vascular stress? A commentary on Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radical Biol Med 43:506-510
48. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A (2007) sRAGE but not esRAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9-13
49. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569
50. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653
51. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
52. Jax TW (2010) Metabolic memory: a vascular perspective. Cardiovasc Diabetol 9:51
53. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R (1993) Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649-1656
54. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85:87-91
55. Ahmed KA, Muniandy S, Ismail IS (2007) Role of Nε-(carboxymethyl) lysine in the development of ischemic heart disease in type 2 diabetes mellitus. J Clin Biochem Nutr 41:97-105
56. Gul A, Rathman MA, Salim A, Simjee SU (2008) Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. AGE 30:303-309
57. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L (2009) Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 57:1874-1880
58. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M (2007) Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50:1409-1417
59. Nin JWM, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, Tarnow L, Rossing P, Stehouwer CDA (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes Care 34:442-447
60. Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P (2005) Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 49:685-690
61. Taki K, Tsuruta Y, Niwa T (2008) Cardiac troponin T and advanced glycation end-products in hemodialysis patients. Am J Nephrol 28:701-706
62. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205:544-548
63. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, Chen QJ, Wang JG, De Caterina R, Shen WF (2009) Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 206:540-545
64. Peng WH, Lu L, Hu J, Yan XX, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem 42:1252-1259
65. Piarulli F, Ragazzi E, Sartore G, Reitano R, Nollino L, Cosma C, Sechi A, Fedele D, Lapolla A (2008) Role of endogenous secretory rage (esRAGE) in micro- and macro-vascular complications in a group of type 2 diabetic patients. Diabetes Vasc Dis Res 5:367-368 (abstract)
66. Basta G, Del Turco S, Marchi F, Navarra T, Battaglia D, Mercuri A, Mazzone A, Berti S (2011) Elevated soluble receptor for advanced glycation end product levels in patients with acute coronary syndrome and positive cardiac troponin I. Coron Artery Dis 22:590-594
67. Nin JWM, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, Tarnow L, Rossing P, Stehouwer CDA (2010) Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes 59:2027-2032
68. Park H-J, Baek J-Y, Shin WS, Kim D-B, Jang SW, Shin DI, Koh YS, Seo SM, Uhm J-S, Kim TH, Kim CJ, Kim PJ, Chang K, Chung WS, Seung K-B, Lee JM (2011) Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 75:1685-1690
69. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, DeMicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH (2011) Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2. Diabetes 60:2379-2385
70. Chen G, Cai L, Chen B, Liang J, Lin F, Li L, Lin L, Yao J, Wen J, Huang H (2011) Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care 34:2586-2590
71. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Circulation 108:1070-1077
72. Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM (2012) Association between sRAGE, esRAGE levels and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Atherosclerosis 220:402-406
73. Sartore G, Piarulli F, Ragazzi E, Burlina S, Chilelli NC, Sarais C, Marin R, Manzato E, Fedele D, Lapolla A (2011) Subclinical diastolic dysfunction in type 2 diabetic patients with and without carotid atherosclerosis: relationship with glyco-oxidation, lipid-oxidation and antioxidant status. Int J Cardiol. Jun 20 [Epub ahead of print]